[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100548743":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":35,"collaborators":7,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":7,"eligibilityCriteria":43,"healthyVolunteers":40,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":7,"studyType":50,"phases":7,"briefSummary":51,"conditions":52,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},{"fullName":5,"class":6},"Belgian Research on AIDS and HIV Consortium","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Stéphane De Wit, MD\u002FPhD","Belgian Research on AIDS & HIV Consortium","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Rakan Nasreddine, MD","CONTACT","+32 2 535 4130","rakan.nasreddine@stpierre-bru.be",[20],{"facility":21,"status":22,"city":23,"state":7,"zip":7,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Saint-Pierre University Hospital","RECRUITING","Brussels","Belgium","BE",{"type":27,"coordinates":28},"Point",[29,30],4.34878,50.85045,{"lat":30,"lon":29},[33],{"name":34,"role":16,"phone":7,"phoneExt":7,"email":7},"Stéphane De Wit",{"type":12,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Rakan Nasreddine","Head of Research","100548743","use-of-long-acting-injectable-cabotegravirrilpivirine-for-the-treatment-of-hiv-in-belgium-100548743",false,"NCT06424964","Use of Long-Acting Injectable Cabotegravir\u002FRilpivirine for the Treatment of HIV in Belgium","Inclusion Criteria:\n\n* HIV-1 patients, aged 18 years and above, having received at least 1 dose of LAI CAB\u002FRPV between September 1, 2021, and March 31, 2024.","ALL","18 Years","99 Years",{"count":48,"type":49},600,"ESTIMATED","OBSERVATIONAL","This will be a multi-center, single arm observational cohort study with an assessment of patient-reported outcomes (PROs) and of clinical and virologic outcomes.\n\nPrimary outcome • Evaluate patient perception of, and satisfaction with, long-acting injectable (LAI) cabotegravir\u002Frilpivirine (CAB\u002FRPV) for the treatment of HIV\n\nSecondary outcomes\n\n• Description of the demographic, HIV-, and non-HIV-related characteristics of participants included in this analysis",[53],"Human Immunodeficiency Virus","2025-02-04",{"date":56,"type":57},"2025-02-05","ACTUAL",{"date":59,"type":57},"2025-01-13",{"date":61,"type":49},"2025-07",{"name":5,"class":6},1]